These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 10715299)
1. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299 [TBL] [Abstract][Full Text] [Related]
2. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749 [TBL] [Abstract][Full Text] [Related]
3. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883 [TBL] [Abstract][Full Text] [Related]
4. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483 [TBL] [Abstract][Full Text] [Related]
7. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
9. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048 [TBL] [Abstract][Full Text] [Related]
10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174 [TBL] [Abstract][Full Text] [Related]
11. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409 [TBL] [Abstract][Full Text] [Related]
12. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342 [TBL] [Abstract][Full Text] [Related]
13. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971 [TBL] [Abstract][Full Text] [Related]
14. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
15. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087 [TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group. Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Land VJ; Shuster JJ; Crist WM; Ravindranath Y; Harris MB; Krance RA; Pinkel D; Pullen DJ J Clin Oncol; 1994 Sep; 12(9):1939-45. PubMed ID: 8083715 [TBL] [Abstract][Full Text] [Related]
18. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252 [TBL] [Abstract][Full Text] [Related]
19. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525 [TBL] [Abstract][Full Text] [Related]
20. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]